Pci Pharma Services
Pci Pharma Services is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients with Inadequately Controlled Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI)
Sponsor Rezolute Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)
Sponsor Glaukos Corp.
- Start (EU)
- Latest update
- Estimated end
Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age with Dravet Syndrome
Sponsor UCB Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multi-Center, Open Label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
Sponsor Ns Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
Sponsor Eip Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
Single-arm, open label, multicenter clinical study to evaluate the handling and safety of AVT06 pre-filled syringe (PFS) in subjects with chorioretinal vascular disease followed by an optional extension phase of AVT06 pre-filled syringe (PFS).
Sponsor Alvotech Swiss AG
- Start (EU)
- Latest update
- Estimated end
Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality
Sponsor Instituto Grifols S.A.
- Start (EU)
- Latest update
- Estimated end
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome – Acute Kidney Injury
Sponsor River 2 Renal Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer
Sponsor Essa Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Pci Pharma Services?
The 2026-10-09 snapshot links Pci Pharma Services to 9 distinct CTIS trials. Recorded services include Medicinal product management, Compounding and Filling of the product for commercial and clinical use, IMP packaging and labeling, IP packaging, labeling, storage, distribution and QP services, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Pci Pharma Services?
The most frequently recorded therapeutic areas are Endocrinology, Neurology, Ophthalmology, Solid Tumor Oncology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Pci Pharma Services conducted?
The linked trials record locations in 17 countries, including Spain, Italy, Germany, France, Belgium. These are trial locations, not confirmed office locations or countries where Pci Pharma Services delivered services.
What can this page tell me about Pci Pharma Services's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Pci Pharma Services. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- PCI Pharma Services
- Pci Pharma Services